Prostatype Genomics FCF per Share
The Free Cash Flow per Share of Prostatype Genomics (PROGEN.ST) as of Oct 13, 2026 is -0.47 SEK. In the previous year, Free Cash Flow per Share was -24.02 SEK — a change of -98.03% (higher).
Get this data via API
Financial Data API
FCF per Share
-0.47SEK
YoY
-98.03%
Last updated:
The Prostatype Genomics FCF per Share history
3 Years
10 Years
25 Years
Max
| YEAR | FCF per Share | YoY |
|---|---|---|
| -0.47SEK | -98.03% | |
| -24.02SEK | -93.21% | |
| -353.66SEK | +2,797.16% | |
| -12.21SEK | +3.00% | |
| -11.85SEK | +804.22% | |
| -1.31SEK | +58.95% | |
| -0.82SEK | +278.60% | |
| -0.22SEK | +24.31% | |
| -0.18SEK | +7.38% | |
| -0.16SEK | — |
Prostatype Genomics Stock analysis
Frequently Asked Questions about Prostatype Genomics stock
Free Cash Flow per Share of Prostatype Genomics is -0.47 SEK in 2025.
Free Cash Flow per Share of Prostatype Genomics changed from -24.02 SEK to -0.47 SEK, representing a -98.03% change. The value is higher than the previous year.
On Eulerpool you can find the complete historical development of Free Cash Flow per Share Prostatype Genomics since 2006 – with annual values, charts, and detailed analysis.
FCF per share measures the free cash flow allocated to each outstanding share. It is a key metric for assessing shareholder value creation.
Cash Flow — Prostatype Genomics
All Key Metrics — Prostatype Genomics
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth